Mostrar el registro sencillo del ítem
dc.contributor.author | Iglesies-Grau, Josep | |
dc.contributor.author | Garcia-Alvarez, Ana | |
dc.contributor.author | Oliva, Belen | |
dc.contributor.author | Mendieta, Guiomar | |
dc.contributor.author | Garcia-Lunar, Ines | |
dc.contributor.author | Fuster, Jose J. | |
dc.contributor.author | Devesa, Ana | |
dc.contributor.author | Pérez-Herreras, Cristina | |
dc.contributor.author | Fernandez-Ortiz, Antonio | |
dc.contributor.author | Brugada, Ramon | |
dc.contributor.author | Ibáñez, Borja | |
dc.contributor.author | Fernandez-Jimenez, Rodrigo | |
dc.contributor.author | Fuster, Valentin | |
dc.date.accessioned | 2024-05-09T13:59:57Z | |
dc.date.available | 2024-05-09T13:59:57Z | |
dc.date.issued | 2023-12-19 | |
dc.identifier.citation | Cardiovasc Diabetol. 2023 Dec 19;22(1):350. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19335 | |
dc.description.abstract | BACKGROUND Elevated glycated hemoglobin (HbA1c) is associated with a higher burden of subclinical atherosclerosis (SA). However, the association with SA of earlier insulin resistance markers is poorly understood. The study assessed the association between the homeostatic model assessment of insulin resistance index (HOMA-IR) and SA in addition to the effect of cardiovascular risk factors (CVRFs) in individuals with normal HbA1c. METHODS A cohort of 3,741 middle-aged individuals from the Progression of Early Subclinical Atherosclerosis (PESA) study with basal HbA1c < 6.0% (< 42 mmol/mol) and no known CV disease underwent extensive imaging (multiterritorial vascular ultrasound and coronary artery calcium score, CACS) to assess the presence, burden, and extent of SA. RESULTS Individuals with higher HOMA-IR values had higher rates of CVRFs. HOMA-IR showed a direct association with the multiterritorial extent of SA and CACS (p < 0.001) and with global plaque volume measured by 3-dimensional vascular ultrasound (p < 0.001). After adjusting for key CVRFs and HbA1c, HOMA-IR values ≥ 3 were associated with both the multiterritorial extent of SA (odds ratio 1.41; 95%CI: 1.01 to 1.95, p = 0.041) and CACS > 0 (odds ratio 1.74; 95%CI: 1.20 to 2.54, p = 0.004), as compared with the HOMA-IR < 2 (the reference HOMA-IR category). In a stratified analysis, this association remained significant in individuals with a low-to-moderate SCORE2 risk estimate (75.6% of the cohort) but not in high-risk individuals. CONCLUSIONS The use of HOMA-IR identified low-risk individuals with a higher burden of SA, after adjusting for the effects of key traditional CVRFs and HbA1c. HOMA-IR is a simple measure that could facilitate earlier implementation of primary CV prevention strategies in clinical practice. | es_ES |
dc.description.sponsorship | The PESA study is co-funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, and Banco Santander, Madrid, Spain. The study also receives funding from the Instituto de Salud Carlos III (ISCIII) (PI15/02019) and the European Regional Development Fund (ERDF) “Una manera de hacer Europa”. RF-J is the recipient of grants PI19/01704 and PI22/01560 funded by the ISCIII-Fondo de Investigación Sanitaria and co-funded by the European Union. The CNIC is supported by the ISCIII, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020- 001041-S funded by MICIN/AEI/https://doi.org/10.13039/501100011033). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central (BMC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Insulin Resistance | es_ES |
dc.subject.mesh | Atherosclerosis | es_ES |
dc.subject.mesh | Plaque, Atherosclerotic | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Glycated Hemoglobin | es_ES |
dc.subject.mesh | Risk Factors | es_ES |
dc.title | Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38115031 | es_ES |
dc.format.volume | 22 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 350 | es_ES |
dc.identifier.doi | 10.1186/s12933-023-02090-1 | es_ES |
dc.contributor.funder | Centro Nacional de Investigaciones Cardiovasculares Carlos III (España) | es_ES |
dc.contributor.funder | Banco Santander | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1475-2840 | es_ES |
dc.relation.publisherversion | 10.1186/s12933-023-02090-1 | es_ES |
dc.identifier.journal | Cardiovascular diabetology | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovascular | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |